Rotavirus vaccines: current prospects and future challenges

  title={Rotavirus vaccines: current prospects and future challenges},
  author={Roger I Glass and Umesh D. Parashar and Joseph S. Bresee and Reina M Turcios and Thea K. Fischer and Marc-Alain Widdowson and Baoming Jiang and Jon R. Gentsch},
  journal={The Lancet},
Rotavirus vaccines: Opportunities and challenges
Rotavirus vaccines remain to be fully evaluated in low-income countries where reduced immunogenicity of oral vaccines, greater strain diversity and difficulties reaching target populations might decrease immunisation programme performance.
Prevention of childhood rotavirus disease through the use of Rotarix™ and RotaTeq™ vaccines
More data on the efficacy of these two new vaccines in low-income nations are needed, particularly in Asia and Africa, before global inclusion of rotavirus vaccines into national immunisation programmes can be recommended.
Introduction of rotavirus vaccines in developing countries: remaining challenges
Since the majority of childhood deaths from rotavirus occur in the developing countries of Africa and Asia, widespread use of vaccine in these two continents will be necessary before a major impact on global diarrhoea mortality is seen.
Incorporation of a rotavirus vaccine into the national immunisation schedule in the United Kingdom: a review
This article provides a review of the product profile of the Rotarix vaccine for use in the national immunisation programme in the UK from an expert perspective and concludes that this single G1P[8] strain-based human rotavirus vaccine has demonstrated high efficacy in preventing severe rotav virus gastroenteritis in the first 3 years of life in middle- and high-income countries.
Assessing the effectiveness and public health impact of rotavirus vaccines after introduction in immunization programs.
Data is reviewed for the protective efficacy of the 2 new rotavirus vaccines, with emphasis on issues particularly important for consideration as these vaccines are introduced in routine infant immunization programs.
Rotavirus vaccines in developed countries
Large-scale safety and efficacy studies of two new live, oral, attenuated vaccines have shown excellent efficacy against severe rotavirus gastroenteritis, and both studies detected no association with intussusception with these new vaccines when administered at the scheduled ages.
Performance of rotavirus vaccines in developed and developing countries
Previous candidate rotavirus vaccines and vaccines in current use are reviewed, with emphasis on their performance in developed versus developing countries, and future efforts for these vaccines should focus on optimizing the efficacy and delivery.
Rotavirus vaccines in routine use.
  • J. Tate, U. Parashar
  • Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2014
The risk-benefit analysis of rotavirus vaccines is extremely favorable but other strategies to improve the effectiveness of the vaccine, particularly in lower middle income settings, should be considered.


Epidemiology of rotavirus diarrhoea in Africa: a review to assess the need for rotavirus immunization.
C cumulative experience from 15 African countries suggests that rotavirus is the most important cause of severe diarrhoea in African children and that most strains in circulation today belong to common G types that are included in reassortant vaccines.
Rotavirus vaccines: targeting the developing world.
For the global effort toward the prevention of rotavirus disease to be successful, special efforts will be required in India, China, and Indonesia, because one-third of all deaths due to rotav virus disease occur in these countries, and because these countries depend almost entirely on vaccines manufactured domestically.
A Rotavirus Vaccine for Prophylaxis of Infants Against Rotavirus Gastroenteritis
Results show prospects for widespread use of Rotarix to reduce rotavirus disease burden and warrant continued worldwide evaluation.
Development of candidate rotavirus vaccines derived from neonatal strains in India.
This unique project, which is developing a new rotavirus vaccine in India with the use of Indian strains, an Indian manufacturer, and an Indian clinical development program, aims to expedite introduction of rotav virus vaccines in India.
Efficacy of RIX4414 Live Attenuated Human Rotavirus Vaccine in Finnish Infants
RIX4414 strain of G1 human rotavirus vaccine was well-tolerated, immunogenic and efficacious in infants againstRotavirus gastroenteritis during a 2-year period, and a higher dose of this vaccine may be considered for future efficacy trials.
The global burden of diarrhoeal disease in children.
The decline in global diarrhoea mortality is confirmed by detailed information from monitoring in certain countries over time, and increased use of oral rehydration therapy, improved nutrition, increased breastfeeding, better supplemental feeding, female education, measles immunization and improvements in hygiene and sanitation are believed to have contributed to this decline.
Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela.
In this study in a developing country, the quadrivalent rhesus rotav virus-based vaccine induced a high level of protection against severe diarrheal illness caused by rotavirus.